啟迪藥業(000590.SZ):控股股東所持7043.2804萬股被司法凍結
格隆匯6月22日丨啟迪藥業(000590.SZ)公佈,公司於近日通過中國證券登記結算有限責任公司深圳分公司(“中登結算公司”)系統查詢和收到控股股東啟迪科服發來的《吿知函》,獲悉公司控股股東啟迪科服持有的公司部分股份被司法凍結,此次凍結7043.2804萬股。
控股股東啟迪科服於2019年4月25日發行的2019年第一期啟迪科技服務有限公司公司債券(發行總額5億元,期限10年,在第5個計息年度末附發行人調整票面利率選擇權及投資者回售選擇權),由於可能觸發加速到期條款導致立即兑付,債權代理人海通證券向北京金融法院申請財產保全,導致控股股東啟迪科服所持公司部分股份被凍結。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.